Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.

Cyrille Hulin,Philippe Moreau,Michel Attal,Karim Belhadj,Lotfi Benboubker,Denis Caillot,Thierry Facon,Laurent Garderet,Frédérique Kuhnowski,Anne-Marie Stoppa,Brigitte Kolb,Mourad Tiab,Pieter Sonneveld,Kon-Siong G. Jie,Matthijs Westerman,Lixia Pei,Tobias Kampfenkel,Carla de Boer,Jessica Vermeulen,Niels W.C.J. van de Donk,Hovon

Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.

2019

8042Background: High-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) is the standard of care in TE NDMM. In the phase 3 CASSIOPEIA study, D-VTd significantly improved str...

Keywords:

Bortezomib/thalidomide
Pathology
Dexamethasone
Oncology
Daratumumab
Stem cell
Multiple myeloma
Internal medicine
Medicine
Transplantation
newly diagnosed
standard of care

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations